Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells1. Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-κB pathway2,3 that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified4. Here we report recurrent somatic mutations affecting the polycomb-group oncogene5 EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27). After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types6, EZH2 is the second histone methyltransferase gene found to be mutated in cancer. These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs. Our data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymatic activity in vitro.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
Molecular Cancer Open Access 21 February 2023
Parallel functional annotation of cancer-associated missense mutations in histone methyltransferases
Scientific Reports Open Access 02 November 2022
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
BMC Cancer Open Access 14 September 2022
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Alizadeh, A.A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009).
Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712–716 (2009).
Bea, S. et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106, 3183–3190 (2005).
Kleer, C.G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11606–11611 (2003).
van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521–523 (2009).
Morin, R. et al. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 45, 81–94 (2008).
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–628 (2008).
Ley, T.J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66–72 (2008).
Kirmizis, A. et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18, 1592–1605 (2004).
Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008).
Southall, S.M., Wong, P.S., Odho, Z., Roe, S.M. & Wilson, J.R. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol. Cell 33, 181–191 (2009).
Dillon, S.C., Zhang, X., Trievel, R.C. & Cheng, X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6, 227 (2005).
Joshi, P. et al. Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2. J. Biol. Chem. 283, 27757–27766 (2008).
Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
Raaphorst, F.M. et al. Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J. Immunol. 164, 1–4 (2000).
Su, I.H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124–131 (2003).
van Kemenade, F.J. et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97, 3896–3901 (2001).
Couture, J.F., Dirk, L.M., Brunzelle, J.S., Houtz, R.L. & Trievel, R.C. Structural origins for the product specificity of SET domain protein methyltransferases. Proc. Natl. Acad. Sci. USA 105, 20659–20664 (2008).
O'Riain, C. et al. Array-based DNA methylation profiling in follicular lymphoma. Leukemia 23, 1858–1866 (2009).
Martín-Subero, J.I. et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113, 2488–2497 (2009).
Viré, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871–874 (2006).
Hans, C.P. et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101, 2363–2367 (2003).
Thompson, J.D., Gibson, T.J. & Higgins, D.G. Multiple sequence alignment using ClustalW and ClustalX. Curr. Protoc. Bioinformatics 00, 2.3.1–2.3.22 (2002).
Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341–346 (2001).
Krzywinski, M. et al. A BAC clone fingerprinting approach to the detection of human genome rearrangements. Genome Biol. 8, R224 (2007).
Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 18, 1851–1858 (2008).
Shah, S.P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813 (2009).
Levy, S. et al. The diploid genome sequence of an individual human. PLoS Biol. 5, e254 (2007).
Wang, J. et al. The diploid genome sequence of an Asian individual. Nature 456, 60–65 (2008).
Bentley, D.R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53–59 (2008).
Kopp, J. & Schwede, T. The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res. 32 Database issue, D230–D234 (2004).
Baskind, H.A. et al. Functional conservation of asxl2, a murine homolog for the Drosophila enhancer of trithorax and polycomb group gene asx. PLoS One 4, e4750 (2009).
Beckwith, M., Longo, D.L., O'Connell, C.D., Moratz, C.M. & Urba, W.J. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J. Natl. Cancer Inst. 82, 501–509 (1990).
Dyer, M.J., Fischer, P., Nacheva, E., Labastide, W. & Karpas, A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations. Blood 75, 709–714 (1990).
Epstein, A.L. et al. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 42, 2379–2391 (1978).
Al-Katib, A.M. et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res. 4, 1305–1314 (1998).
Tweeddale, M.E. et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69, 1307–1314 (1987).
Wright, G. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 100, 9991–9996 (2003).
Cheung, K.J. et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113, 137–148 (2009).
Delaney, A.D., Qian, H., Friedman, J.M. & Marra, M.A. Use of Affymetrix mapping arrays in the diagnosis of gene copy number variation. Curr. Protoc. Hum. Genet. 59, 8.13.1–8.13.16 (2008).
Shah, S.P. et al. Integrating copy number polymorphisms into array CGH analysis using a robust HMM. Bioinformatics 22, e431–e439 (2006).
This study was funded in part by grants from the National Cancer Institute Office of Cancer Genomics (see below), the National Cancer Institute of Canada (NCIC) Terry Fox Foundation New Frontiers Program Project Grant (grant no. 016003/grant type 230/project title: Biology of Cancer: Follicular Lymphoma as a Model of Cancer Progression) and Genome Canada/Genome BC Grant Competition III (project title: High Resolution Analysis of Follicular Lymphoma Genomes) to J.M.C., M.A.M., R.D.G. and D.E.H. and was supported by The Terry Fox Foundation (grant no. 019001). In addition, N.A.J. is a research fellow of the Terry Fox Foundation through an award from the NCIC (019005) and the Michael Smith Foundation for Health Research (MSFHR) (ST-PDF-01793). M.A.M. is a Terry Fox Young Investigator and a Michael Smith Senior Research Scholar. A.J.M. is supported by a Fellowship Award from The Leukemia & Lymphoma Society. R.D.M. is a Vanier Scholar (Canadian Institutes for Health Research) and is also supported by a MSFHR senior graduate fellowship. The laboratory work for this study was undertaken at the Genome Sciences Centre, British Columbia Cancer Research Centre and the Centre for Translational and Applied Genomics, a program of the Provincial Health Services Authority Laboratories. The authors thank the BC Cancer Foundation and the Lion's Club International for their support. The authors gratefully acknowledge D. Gerhard for helpful discussions. Special thanks to C. Suragh and A. Drobnies for expert project management assistance. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. NO1-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.
Authors H.Z., M.K., P.S., J.F.C. and M.T. are employees of BPS Bioscience. This company manufactures commercial EZH2 assay kits.
About this article
Cite this article
Morin, R., Johnson, N., Severson, T. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42, 181–185 (2010). https://doi.org/10.1038/ng.518
This article is cited by
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
Molecular Cancer (2023)
Nature Chemical Biology (2023)
Ferroptosis-related STEAP3 acts as predictor and regulator in diffuse large B cell lymphoma through immune infiltration
Clinical and Experimental Medicine (2023)
Journal of Experimental & Clinical Cancer Research (2022)
Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma
Journal of Translational Medicine (2022)